Intravitreal Bevacizumab to Treat Iris Neovascularization and Neovascular Glaucoma Secondary to Ischemic Retinal Diseases in 41 Consecutive Cases

Ophthalmology

Volumn 115, Issue 9, 2008, Pages

  Wakabayashi, Taku ^a   Oshima, Yusuke ^a   Sakaguchi, Hirokazu ^a   Ikuno, Yasushi ^a   Miki, Atsuya ^a   Gomi, Fumi ^a   Otori, Yasumasa ^a   Kamei, Motohiro ^a   Kusaka, Shunji ^a   Tano, Yasuo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; CLOSED ANGLE GLAUCOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOPHTHALMITIS; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS NEOVASCULARIZATION; MALE; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA ISCHEMIA; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 50249138759     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.02.026     Document Type: Article

References (31)

1. Sivack-Callcott J.A., O'Day D.M., Gass D.M., and Tsai J.C. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 108 (2001) 1767-1776
2. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
3. Tripathi R.C., Li J., Tripathi B.J., et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 105 (1998) 232-237
4. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114 (1996) 964-970
5. Adamis A.P., Shima D.T., Tolentino M.J., et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114 (1996) 66-71
6. Wand M., Dueker D.K., Aiello L.M., and Grant W.M. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol 86 (1978) 332-339
7. Murphy R.P., and Egbert P.R. Regression of iris neovascularization following panretinal photocoagulation. Arch Ophthalmol 97 (1979) 700-702
8. Tasman W., Magargal L.E., and Augsburger J.J. Effects of argon laser photocoagulation on rubeosis iridis and angle neovascularization. Ophthalmology 87 (1980) 400-402
9. Laatikainen L. A prospective follow-up study of panretinal photocoagulation in preventing neovascular glaucoma following ischaemic central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 220 (1983) 236-239
10. Pavan P.R., Folk J.C., Weingeist T.A., et al. Diabetic rubeosis and panretinal photocoagulation. Arch Ophthalmol 101 (1983) 882-884
11. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29 suppl (2002) 10-14
12. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
13. Ferrara N., Damico L., Shams N., et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006) 859-870
14. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
15. Avery R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 352-354
16. Davidorf F.H., Mouser J.G., and Derick R.J. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26 (2006) 354-356
17. Mason III J.O., Albert Jr. M.A., Mays A., and Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26 (2006) 839-841
18. Oshima Y., Sakaguchi H., Gomi F., and Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142 (2006) 155-158
19. Iliev M.E., Domig D., Wolf-Schnurrbursch U., et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142 (2006) 1054-1056
20. Aiello L.P., Brucker A.J., Chang S., et al. Evolving guidelines for intravitreous injections. Retina 24 suppl (2004) S3-S19
21. Holladay J.T. Proper method for calculating average visual acuity. J Refract Surg 13 (1997) 388-391
22. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
23. Bakri S.J., Snyder M.R., Reid J.M., et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 (2007) 855-859
24. Ishida S., Usui T., Yamashiro K., et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198 (2003) 483-489
25. Inan U.U., Avci B., Kusbeci T., et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48 (2007) 1773-1781
26. Parrish R., and Herschler J. Eyes with end-stage neovascular glaucoma: natural history following successful modified filtering operation. Arch Ophthalmol 101 (1983) 745-746
27. Tsai J.C., Feuer W.J., Parrish II R.K., and Grajewski A.L. 5-Fluorouracil filtering surgery and neovascular glaucoma: long-term follow-up of the original pilot study. Ophthalmology 102 (1995) 887-892
28. Elgin U., Berker N., Batman A., et al. Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. J Glaucoma 15 (2006) 466-470
29. Jonas J.B., Spandau U.H., and Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 39 (2007) 121-122
30. Bartz-Schmidt K.U., Thumann G., Psichias A., et al. Pars plana vitrectomy, endolaser coagulation of the retina and the ciliary body combined with silicone oil endotamponade in the treatment of uncontrolled neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 237 (1999) 969-975
31. Kiuchi Y., Nakae K., Saito Y., et al. Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1627-1632